These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32206324)

  • 1. Risk of hypoglycemia associated with repaglinide combined with clopidogrel, a retrospective cohort study.
    Akagi Y; Iketaki A; Kimura H; Matsudaira Y; Yoshida T; Nishimura T; Kawano Y; Mano Y; Shigematsu E; Ujihara M
    J Pharm Health Care Sci; 2020; 6():5. PubMed ID: 32206324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoglycemia during the Concomitant Use of Repaglinide and Clopidogrel in an Elderly Patient with Type 2 Diabetes and Severe Renal Insufficiency.
    Takayama K; Fujii K; Yamaguchi H; Miyoshi Y; Uehara Y; Nagata S; Obata Y; Kosugi M; Hazama Y; Yasuda T
    Intern Med; 2021; 60(6):905-910. PubMed ID: 33716254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Hypoglycemia and Concomitant Use of Repaglinide and Clopidogrel: A Population-Based Nested Case-Control Study.
    Wei Y; Lin FJ; Lin SY; Wang CC
    Clin Pharmacol Ther; 2019 Dec; 106(6):1346-1352. PubMed ID: 31216051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Efficacy of Repaglinide Versus the Combination of Mitiglinide and Voglibose on Glycemic Variability in Japanese Patients with Type 2 Diabetes.
    Okada H; Tanaka M; Hasegawa G; Nakajima H; Kadono M; Okada Y; Hirata A; Oyamada H; Yamane T; Fukui M
    Curr Pharm Des; 2020; 25(43):4600-4605. PubMed ID: 31538887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
    Kajosaari LI; Niemi M; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
    Malaisse WJ
    Treat Endocrinol; 2003; 2(6):401-14. PubMed ID: 15981944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
    Scheen AJ
    Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy.
    Kaku K; Inagaki N; Kobayashi N
    Diabetes Ther; 2014 Jun; 5(1):97-111. PubMed ID: 24488695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced blood glucose levels by the combination of vadadustat in an elderly patient with chronic kidney disease who was receiving mitiglinide and sitagliptin: a case report.
    Takakura A; Hirai T; Hamaguchi N; Mukohara R; Matsumoto K; Yano Y; Iwamoto T
    J Pharm Health Care Sci; 2023 Dec; 9(1):46. PubMed ID: 38072987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C8-mediated interaction between repaglinide and steviol acyl glucuronide: In vitro investigations using rat and human matrices and in vivo pharmacokinetic evaluation in rats.
    Xu Y; Zhou D; Wang Y; Li J; Wang M; Lu J; Zhang H
    Food Chem Toxicol; 2016 Aug; 94():138-47. PubMed ID: 27259818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions.
    Tornio A; Filppula AM; Kailari O; Neuvonen M; Nyrönen TH; Tapaninen T; Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2014 Oct; 96(4):498-507. PubMed ID: 24971633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
    Kajosaari LI; Jaakkola T; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2006 Mar; 62(3):217-23. PubMed ID: 16447051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy.
    Tanaka K; Okada Y; Mori H; Torimoto K; Arao T; Tanaka Y
    Intern Med; 2018 Jan; 57(1):65-70. PubMed ID: 29021480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
    Johansen OE; Birkeland KI
    Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Miglitol- or Repaglinide-Based Combination Therapy with Alogliptin for Drug-Naïve Patients with Type 2 Diabetes: An Open-Label, Single-Center, Parallel, Randomized Controlled Pilot Study.
    Okajima F; Sugihara H; Emoto N
    J Nippon Med Sch; 2021 Mar; 88(1):71-79. PubMed ID: 32475902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information.
    Kim SJ; Yoshikado T; Ieiri I; Maeda K; Kimura M; Irie S; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2016 Oct; 44(10):1622-32. PubMed ID: 27457785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
    Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
    Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of both fasting and postprandial glycemic control by the two-step addition of miglitol and mitiglinide to basal insulin therapy: a pilot study.
    Ihana N; Tsujimoto T; Yamamoto-Honda R; Kishimoto M; Kajio H; Noto H; Kakei M; Noda M
    Diabetol Metab Syndr; 2014; 6():48. PubMed ID: 24684803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe hypoglycemia from clarithromycin-repaglinide drug interaction.
    Khamaisi M; Leitersdorf E
    Pharmacotherapy; 2008 May; 28(5):682-4. PubMed ID: 18447665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.